Mar 31, 2026 8:05am EDT Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Mar 3, 2026 4:01pm EST Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
